Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer

Zia Rahman, John Kavanagh, Richard Champlin, Richard Giles, Elie Hanania, Siqinq Fu, Zifei Zu, Rakesh Mehra, Frankie Holmes, Andrzej Kudelka, David Claxton, Claire Verschraegen, James Gajewski, Michael Andreeff, Shelly Heimfeld, Ronald Berenson, Debra Ellerson, Leslie Calvert, Eugene Mechetner, Tanya Holzmayer & 10 others Andrew Dayne, Joy Hamer, Carlos Bachier, Jeffrey Ostrove, Donna Przepiorka, Barbara Burtness, Richard Cote, Robert Bast, Gabriel Hortobagyi, Albert Deisseroth

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Most patients relapse after high-dose chemotherapy (HDCT) with autologous stem-cell transplantation (ASCT) for metastatic breast cancer. Further chemotherapy immediately after hematopoietic recovery from ASCT is not given for fear of irreversibly damaging the newly engrafted stem cells. In a pilot chemoprotection trial, autologous CD34+ cells from patients with metastatic breast cancer were exposed to a replication-incompetent retrovital vector carrying MDR-1 cDNA and then reinfused after HDCT. Immediately on recovery, patients received multiple courses of escalating dose paclitaxel. All of the 10 patients tolerated reinfusion of modified cells without any toxicity and had myeloid engraftment within 12 days (range, 11-14). The bone marrow cells of three patients contained vector MDR-1-positive cells only at the time of the first course of posttransplant paclitaxel, indicating that the MDR-1 vector-modified cells had only short-term engrafting potential. A total of 83 courses of paclitaxel were administered starting at a median of 30 (range, 21-32) days from ASCT. The median dose of paclitaxel was 225 mg/m2 and the median interval between paclitaxel cycles of therapy was 21 (range, 20-41) days. Five of the six CR patients were able to receive all of the 12 courses of paclitaxel. Three patients who had achieved less than a complete response to the HDCT (2 patients) and partial response (1 patient) were converted to complete clinical responses during the 12 cycles of paclitaxel. No delayed toxicity or bone marrow failure was noted in these patients with a median follow-up of 2 years from ASCT. This is the first study of chemotherapy immediately after transplantation with autologous CD34+ cells. These data indicate that paclitaxel can be safely administered immediately after ASCT without any delayed toxicities. Paclitaxel given immediately after ASCT can further improve the response to pretransplant chemotherapy in patients with advanced breast cancer.

Original languageEnglish (US)
Pages (from-to)2717-2721
Number of pages5
JournalClinical Cancer Research
Volume4
Issue number11
StatePublished - Nov 1 1998

Fingerprint

Stem Cell Transplantation
Paclitaxel
Breast Neoplasms
Drug Therapy
Autologous Transplantation
Bone Marrow Cells
Fear
Stem Cells
Complementary DNA
Bone Marrow
Recurrence

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Rahman, Z., Kavanagh, J., Champlin, R., Giles, R., Hanania, E., Fu, S., ... Deisseroth, A. (1998). Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer. Clinical Cancer Research, 4(11), 2717-2721.
Rahman, Zia ; Kavanagh, John ; Champlin, Richard ; Giles, Richard ; Hanania, Elie ; Fu, Siqinq ; Zu, Zifei ; Mehra, Rakesh ; Holmes, Frankie ; Kudelka, Andrzej ; Claxton, David ; Verschraegen, Claire ; Gajewski, James ; Andreeff, Michael ; Heimfeld, Shelly ; Berenson, Ronald ; Ellerson, Debra ; Calvert, Leslie ; Mechetner, Eugene ; Holzmayer, Tanya ; Dayne, Andrew ; Hamer, Joy ; Bachier, Carlos ; Ostrove, Jeffrey ; Przepiorka, Donna ; Burtness, Barbara ; Cote, Richard ; Bast, Robert ; Hortobagyi, Gabriel ; Deisseroth, Albert. / Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer. In: Clinical Cancer Research. 1998 ; Vol. 4, No. 11. pp. 2717-2721.
@article{8e819b3d8635483ea38776151558a578,
title = "Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer",
abstract = "Most patients relapse after high-dose chemotherapy (HDCT) with autologous stem-cell transplantation (ASCT) for metastatic breast cancer. Further chemotherapy immediately after hematopoietic recovery from ASCT is not given for fear of irreversibly damaging the newly engrafted stem cells. In a pilot chemoprotection trial, autologous CD34+ cells from patients with metastatic breast cancer were exposed to a replication-incompetent retrovital vector carrying MDR-1 cDNA and then reinfused after HDCT. Immediately on recovery, patients received multiple courses of escalating dose paclitaxel. All of the 10 patients tolerated reinfusion of modified cells without any toxicity and had myeloid engraftment within 12 days (range, 11-14). The bone marrow cells of three patients contained vector MDR-1-positive cells only at the time of the first course of posttransplant paclitaxel, indicating that the MDR-1 vector-modified cells had only short-term engrafting potential. A total of 83 courses of paclitaxel were administered starting at a median of 30 (range, 21-32) days from ASCT. The median dose of paclitaxel was 225 mg/m2 and the median interval between paclitaxel cycles of therapy was 21 (range, 20-41) days. Five of the six CR patients were able to receive all of the 12 courses of paclitaxel. Three patients who had achieved less than a complete response to the HDCT (2 patients) and partial response (1 patient) were converted to complete clinical responses during the 12 cycles of paclitaxel. No delayed toxicity or bone marrow failure was noted in these patients with a median follow-up of 2 years from ASCT. This is the first study of chemotherapy immediately after transplantation with autologous CD34+ cells. These data indicate that paclitaxel can be safely administered immediately after ASCT without any delayed toxicities. Paclitaxel given immediately after ASCT can further improve the response to pretransplant chemotherapy in patients with advanced breast cancer.",
author = "Zia Rahman and John Kavanagh and Richard Champlin and Richard Giles and Elie Hanania and Siqinq Fu and Zifei Zu and Rakesh Mehra and Frankie Holmes and Andrzej Kudelka and David Claxton and Claire Verschraegen and James Gajewski and Michael Andreeff and Shelly Heimfeld and Ronald Berenson and Debra Ellerson and Leslie Calvert and Eugene Mechetner and Tanya Holzmayer and Andrew Dayne and Joy Hamer and Carlos Bachier and Jeffrey Ostrove and Donna Przepiorka and Barbara Burtness and Richard Cote and Robert Bast and Gabriel Hortobagyi and Albert Deisseroth",
year = "1998",
month = "11",
day = "1",
language = "English (US)",
volume = "4",
pages = "2717--2721",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

Rahman, Z, Kavanagh, J, Champlin, R, Giles, R, Hanania, E, Fu, S, Zu, Z, Mehra, R, Holmes, F, Kudelka, A, Claxton, D, Verschraegen, C, Gajewski, J, Andreeff, M, Heimfeld, S, Berenson, R, Ellerson, D, Calvert, L, Mechetner, E, Holzmayer, T, Dayne, A, Hamer, J, Bachier, C, Ostrove, J, Przepiorka, D, Burtness, B, Cote, R, Bast, R, Hortobagyi, G & Deisseroth, A 1998, 'Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer', Clinical Cancer Research, vol. 4, no. 11, pp. 2717-2721.

Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer. / Rahman, Zia; Kavanagh, John; Champlin, Richard; Giles, Richard; Hanania, Elie; Fu, Siqinq; Zu, Zifei; Mehra, Rakesh; Holmes, Frankie; Kudelka, Andrzej; Claxton, David; Verschraegen, Claire; Gajewski, James; Andreeff, Michael; Heimfeld, Shelly; Berenson, Ronald; Ellerson, Debra; Calvert, Leslie; Mechetner, Eugene; Holzmayer, Tanya; Dayne, Andrew; Hamer, Joy; Bachier, Carlos; Ostrove, Jeffrey; Przepiorka, Donna; Burtness, Barbara; Cote, Richard; Bast, Robert; Hortobagyi, Gabriel; Deisseroth, Albert.

In: Clinical Cancer Research, Vol. 4, No. 11, 01.11.1998, p. 2717-2721.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer

AU - Rahman, Zia

AU - Kavanagh, John

AU - Champlin, Richard

AU - Giles, Richard

AU - Hanania, Elie

AU - Fu, Siqinq

AU - Zu, Zifei

AU - Mehra, Rakesh

AU - Holmes, Frankie

AU - Kudelka, Andrzej

AU - Claxton, David

AU - Verschraegen, Claire

AU - Gajewski, James

AU - Andreeff, Michael

AU - Heimfeld, Shelly

AU - Berenson, Ronald

AU - Ellerson, Debra

AU - Calvert, Leslie

AU - Mechetner, Eugene

AU - Holzmayer, Tanya

AU - Dayne, Andrew

AU - Hamer, Joy

AU - Bachier, Carlos

AU - Ostrove, Jeffrey

AU - Przepiorka, Donna

AU - Burtness, Barbara

AU - Cote, Richard

AU - Bast, Robert

AU - Hortobagyi, Gabriel

AU - Deisseroth, Albert

PY - 1998/11/1

Y1 - 1998/11/1

N2 - Most patients relapse after high-dose chemotherapy (HDCT) with autologous stem-cell transplantation (ASCT) for metastatic breast cancer. Further chemotherapy immediately after hematopoietic recovery from ASCT is not given for fear of irreversibly damaging the newly engrafted stem cells. In a pilot chemoprotection trial, autologous CD34+ cells from patients with metastatic breast cancer were exposed to a replication-incompetent retrovital vector carrying MDR-1 cDNA and then reinfused after HDCT. Immediately on recovery, patients received multiple courses of escalating dose paclitaxel. All of the 10 patients tolerated reinfusion of modified cells without any toxicity and had myeloid engraftment within 12 days (range, 11-14). The bone marrow cells of three patients contained vector MDR-1-positive cells only at the time of the first course of posttransplant paclitaxel, indicating that the MDR-1 vector-modified cells had only short-term engrafting potential. A total of 83 courses of paclitaxel were administered starting at a median of 30 (range, 21-32) days from ASCT. The median dose of paclitaxel was 225 mg/m2 and the median interval between paclitaxel cycles of therapy was 21 (range, 20-41) days. Five of the six CR patients were able to receive all of the 12 courses of paclitaxel. Three patients who had achieved less than a complete response to the HDCT (2 patients) and partial response (1 patient) were converted to complete clinical responses during the 12 cycles of paclitaxel. No delayed toxicity or bone marrow failure was noted in these patients with a median follow-up of 2 years from ASCT. This is the first study of chemotherapy immediately after transplantation with autologous CD34+ cells. These data indicate that paclitaxel can be safely administered immediately after ASCT without any delayed toxicities. Paclitaxel given immediately after ASCT can further improve the response to pretransplant chemotherapy in patients with advanced breast cancer.

AB - Most patients relapse after high-dose chemotherapy (HDCT) with autologous stem-cell transplantation (ASCT) for metastatic breast cancer. Further chemotherapy immediately after hematopoietic recovery from ASCT is not given for fear of irreversibly damaging the newly engrafted stem cells. In a pilot chemoprotection trial, autologous CD34+ cells from patients with metastatic breast cancer were exposed to a replication-incompetent retrovital vector carrying MDR-1 cDNA and then reinfused after HDCT. Immediately on recovery, patients received multiple courses of escalating dose paclitaxel. All of the 10 patients tolerated reinfusion of modified cells without any toxicity and had myeloid engraftment within 12 days (range, 11-14). The bone marrow cells of three patients contained vector MDR-1-positive cells only at the time of the first course of posttransplant paclitaxel, indicating that the MDR-1 vector-modified cells had only short-term engrafting potential. A total of 83 courses of paclitaxel were administered starting at a median of 30 (range, 21-32) days from ASCT. The median dose of paclitaxel was 225 mg/m2 and the median interval between paclitaxel cycles of therapy was 21 (range, 20-41) days. Five of the six CR patients were able to receive all of the 12 courses of paclitaxel. Three patients who had achieved less than a complete response to the HDCT (2 patients) and partial response (1 patient) were converted to complete clinical responses during the 12 cycles of paclitaxel. No delayed toxicity or bone marrow failure was noted in these patients with a median follow-up of 2 years from ASCT. This is the first study of chemotherapy immediately after transplantation with autologous CD34+ cells. These data indicate that paclitaxel can be safely administered immediately after ASCT without any delayed toxicities. Paclitaxel given immediately after ASCT can further improve the response to pretransplant chemotherapy in patients with advanced breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0031782881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031782881&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 2717

EP - 2721

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 11

ER -

Rahman Z, Kavanagh J, Champlin R, Giles R, Hanania E, Fu S et al. Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer. Clinical Cancer Research. 1998 Nov 1;4(11):2717-2721.